TICKERNERD
Menu
TKNOTKNOHealthcare · Drug Manufacturers - Specialty & Generic

TKNO Stock Forecast: Alpha Teknova, Inc. Price Predictions for 2026-2027

Last close, 7 Oct 2026
$8.71
−0.46% on the day

The 8 Wall Street analysts covering Alpha Teknova, Inc. hold a median 12-month price target of $8.5 — -2.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 6 Oct 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$469.8M
Ticker Nerd rank
96 / 100
Median analyst target
$8.50
Analysts covering
8
Revenue$12.2M+18.5% y/y
Operating income−$2.9M
Net income−$3.2M
Free cash flow−$596K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.1%
1M
+25.9%
YTD
+129.2%
1Y
+66.2%
From 52W high
−6.6%
From 52W low
+337.7%
$1.99
$9.33
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TKNO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Alpha Teknova, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026
96 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
96
Accruals
87
Quality
79
Momentum
73
Issuance
69
Growth
66
Value
60
Size
54
Volatility
26

Revisions (96): Analysts have, on balance, been raising their forecasts.

Volatility (26): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TKNO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TKNO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00Jan 26Apr 26Jul 26Oct 26TKNOHigh $12.00Median $8.50Low $7.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
7 Buy1 Hold0 Sell
Low $7.00Median $8.50High $12.00

The green dot is the last close — the median target sits −2.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Sept 2026JefferiesInitiatesBuy$9.00
11 Aug 2026BTIGUpgradeBuy$8.00
11 Aug 2026BTIGUpgradeBuy—
5 Aug 2026Roth CapitalInitiatesBuy$7.00
5 Aug 2026Roth CapitalInitiatesBuy—
10 July 2024Stephens & Co.ReiteratesOverweight$5.00
10 July 2024Stephens & Co.ReiteratesOverweight—
14 May 2024Stephens & Co.ReiteratesOverweight—
12 Mar 2024BTIGDowngradeNeutral—
12 July 2023KeybancInitiatesSector Weight—
29 June 2023BTIGAssumesBuy$6.00
11 Aug 2022Stephens & Co.MaintainsOverweight—
16 Mar 2022Stephens & Co.MaintainsOverweight—
20 July 2021BTIGInitiatesBuy—
20 July 2021Cowen & Co.InitiatesOutperform—
20 July 2021Stephens & Co.InitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TKNO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

TKNO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 7 Oct 2026, Alpha Teknova, Inc. returned +66.2% against +17.7% for the S&P 500, dividends included.

TKNO vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200Jan 26Apr 26Jul 26Oct 26TKNOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TKNO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Alpha Teknova, Inc. (TKNO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−26.4×

Cheaper than 97% of US stocks

Price / sales
10.4×

Cheaper than 13% of US stocks

Price / book
7.3×

Cheaper than 12% of US stocks

EV / EBITDA
−53.5×

Cheaper than 95% of US stocks

Growth & margins
Revenue growth (YoY)
18.5%

Higher than 67% of US stocks

Earnings growth (YoY)
18.5%

Higher than 57% of US stocks

Gross margin
40.1%

Higher than 49% of US stocks

Operating margin
−23.7%

Higher than 21% of US stocks

Net margin
−38.4%

Higher than 12% of US stocks

Returns & dividend
Return on equity
−24.2%

Higher than 30% of US stocks

Return on assets
−9.3%

Higher than 27% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Alpha Teknova, Inc. (TKNO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Alpha Teknova, Inc. has a market value of $469.8M and an enterprise value of $479.7M.

  • Revenue in the twelve months to 30 June 2026: $43.7M. The latest quarter grew 18.5% year on year.

  • Net income over the same four quarters: −$16.8M, a −38.4% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.31.

  • Free cash flow in the twelve months to 30 June 2026: −$7.4M.

  • Shares outstanding: 53.7M.

  • Trailing P/E: −26.4×; forward P/E: −44.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Alpha Teknova, Inc. employs 158 people — $277K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

TKNO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
TKNOAlpha Teknova, Inc.$469.8M
96
KMDAKamada Ltd.$475.7M
93
EOLSEvolus, Inc.$480.1M
89
GLASGlass House Brands, Inc.$427.3M
37
CGCCanopy Growth Corp.$402.5M
42
TLRYTilray Brands, Inc.$558.6M
14
AQSTAquestive Therapeutics, Inc.$578.6M
53

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Alpha Teknova, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TKNO news & analysis

Teknova and Pluristyx Announce FDA Drug Master File for the PluriFreeze™ Cryopreservation System

GlobeNewsWire · 2 Oct 2026positive

Teknova and Pluristyx announced a Type II FDA Drug Master File for the PluriFreeze cryopreservation system, which is now available for developers to cross-reference in their submissions.

Why it matters — This regulatory filing broadens the accessibility of Teknova's PluriFreeze system to drug developers, potentially expanding its commercial use in the cell and gene therapy space.

All You Need to Know About Alpha Teknova (TKNO) Rating Upgrade to Buy

Zacks Investment Research · 1 Oct 2026positive

Alpha Teknova (TKNO) received a ratings upgrade to a Zacks Rank #2 (Buy), driven by growing optimism about its earnings prospects. The upgrade suggests the stock may move higher based on improving earnings expectations.

Why it matters — A rating upgrade signals improved earnings expectations that a TKNO watcher would want to track.

Alpha Teknova (TKNO) Moves 7.1% Higher: Will This Strength Last?

Zacks Investment Research · 22 Sept 2026neutral

Alpha Teknova (TKNO) rose 7.1% on higher-than-average trading volume in its most recent session. The latest trend in earnings estimate revisions, however, may not help the stock continue moving higher in the near term.

Why it matters — TKNO watchers would note that while the stock saw a notable price gain with elevated volume, the recent earnings estimate revision trend could signal limited near-term upside.

Teknova Expands Custom Manufacturing with Fill-Tek™ Dispensing System for Flexible Single-Use Bag Filling

GlobeNewsWire · 16 Sept 2026positive

Teknova announced the expansion of its custom manufacturing capabilities with the Fill-Tek™ Dispensing System, which fills single-use bag orders across multiple sizes and quantities as a single lot without adding turnaround time.

Why it matters — The added manufacturing capability signals increased operational flexibility and efficiency for Teknova's custom single-use bag filling services, which could support customer demand.

Alpha Teknova Raises Outlook After Record Q2 Revenue at Sidoti Conference

MarketBeat · 20 Aug 2026positive

Alpha Teknova's CFO Matt Lowell, speaking at the Sidoti Conference, said the laboratory and bioprocessing reagents provider is experiencing renewed growth. The company reported record second-quarter revenue and raised its full-year outlook as biopharma funding and life-science end markets improve.

Why it matters — A TKNO watcher would care because record revenue and an improved full-year outlook signal stronger operating momentum tied to a recovering biopharma funding environment.

FAQ

Frequently asked questions about TKNO stock

What is the TKNO stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Alpha Teknova, Inc. have a median 12-month price target of $8.5, with estimates ranging from $7 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TKNO stock a buy right now?

Of the 8 analysts covering Alpha Teknova, Inc., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Alpha Teknova, Inc. 96 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TKNO?

As at 6 Oct 2026, Alpha Teknova, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (96 of 100).

Will TKNO stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies -2.4% from the last close, and Ticker Nerd's factor model ranks Alpha Teknova, Inc. 96 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TKNO stock forecast for 2030?

No analyst covering Alpha Teknova, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TKNO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $12 over the next 12 months.

How has TKNO stock performed over the past year?

Alpha Teknova, Inc. returned +66.2% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Alpha Teknova, Inc. do?

Alpha Teknova, Inc. is a life sciences reagents company that develops and manufactures products used in research, bioprocessing, and molecular diagnostics.

What is the latest news on TKNO?

The most recent item we track (GlobeNewsWire, 2 Oct 2026): "Teknova and Pluristyx Announce FDA Drug Master File for the PluriFreeze™ Cryopreservation System". Teknova and Pluristyx announced a Type II FDA Drug Master File for the PluriFreeze cryopreservation system, which is now available for developers to cross-reference in their submissions.

Company

About Alpha Teknova, Inc.

Alpha Teknova, Inc. is a life sciences reagents company that develops and manufactures products used in research, bioprocessing, and molecular diagnostics. Its offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements, and molecular biology reagents for sample manipulation, resuspension, and purification. The company serves a broad customer base across the biotechnology, pharmaceutical, diagnostics, academic, and government research markets, supporting workflows tied to drug development, vaccine development, and advanced therapies. Alpha Teknova also provides custom and catalog solutions designed for laboratory and manufacturing applications, with products used in cell and gene therapy, synthetic biology, and other life science workflows. Headquartered in Hollister, California, Alpha Teknova plays a specialized role in the supply chain that enables scientific research and the production of biopharmaceutical products.

CEO Mr. Stephen Gunstream · 158 employees · United States · https://www.teknova.com